Carlsmed Inc. Common Stock
Financials
Valuation Metrics
Carlsmed Inc. Common Stock's Market Cap is $408M. At end of 2025 it was $176M. Ranked #2810 of 3,118 in US market (top 90%), #1239 of 1,474 on NASDAQ (top 84%), #177 of 203 in Health Care Equipment & Services (top 87%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $408M | US#2,810/3,118 Sec#177/203 |
| Revenue | $63M | US#2,723/3,118 Sec#192/203 |
| Net Income | $-36M | US—/3,118 Sec—/203 |
| Total Assets | $118M | US#3,039/3,118 Sec#196/203 |
| Net Assets | $84M | US#2,810/3,118 Sec#181/203 |
| Employees | 127 | US#2,571/3,118 Sec#179/203 |
| Value | ||
| P/B | 4.85x | US#2,196/3,118 Sec#130/203 |
| P/S | 6.45x | US#2,480/3,118 Sec#163/203 |
| FCF Yield | -8.38% | US—/3,118 Sec—/203 |
| Profitability | ||
| ROE | -43.14% | US#2,639/3,118 Sec#165/203 |
| ROA | -30.75% | US#2,882/3,118 Sec#188/203 |
| Op. Margin | -61.09% | US#2,666/3,118 Sec#184/203 |
| Revenue Growth | 65.39% | US#163/3,118 Sec#5/203 |
| Financial Health | ||
| Debt Ratio | 40.31% | US#462/3,118 Sec#50/203 |
| Total Debt | $22M | US#2,729/3,118 Sec#171/203 |
| FCF | $-34M | US#2,473/3,118 Sec#173/203 |
| Cash | $46M | US#2,599/3,118 Sec#167/203 |
| Current Ratio | 8.84x | US#288/3,118 Sec#20/203 |
| Performance | ||
| 1Y Return | 16.52% | US#1,239/3,118 Sec#101/203 |
| 1M Return | 5.26% | US#1,136/3,118 Sec#96/203 |
| From 52W High | -12.83% | US#1,051/3,118 Sec#85/203 |
| 1Y MDD | -48.03% | US#2,315/3,118 Sec#152/203 |
| Trading | ||
| Volume | 90,164 shares | US#2,999/3,118 Sec#199/203 |
| Trading Value | $1M | US#3,004/3,118 Sec#191/203 |
| Per Share | ||
| EPS | $-1.34 | US—/3,118 Sec—/203 |
| BPS | $3.10 | US#2,473/3,118 Sec#162/203 |
Company Info
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.